摘要
目的观察每周胸腔注射尿激酶联合静脉导管留置治疗胸膜粘连分隔的效果。方法渗出性胸膜炎60例,随机分成治疗组与对照组各30例。治疗组予胸腔静脉导管留置,每周1次胸腔注射尿激酶10万单位+0.9%氯化钠20ml;对照组常规胸腔穿刺仅注射0.9%氯化钠20ml。两组口服化疗方案均为2SHRZ/4HR。结果治疗8周后,B超检查:形成纤维分隔、粘连及胸膜肥厚,治疗组3例,对照组12例(P<0.01);胸水消失时间:治疗组(18.3±4.2)天,对照组(22.6±5.6)天(P>0.05);胸膜厚度及肺功能FEV1%均有显著差异(P<0.01)。结论胸腔注射尿激酶联合静脉导管留置可以减少胸液分隔,粘连及多房的形成,减轻胸膜肥厚,改善肺功能。
Objective To observe the curative effect of intrapleural urokinase through venous catheter for pletrrisy. Methods Sixty patients with tuberculous pleurisy were randomly divided into 2 groups ： treatment group and control group. The patients in the treatment group were injected with urodinase 100000IU ＋ 0.9% NS 20ml through indwelling venous catheter intrapleurally each time, and the patients in the control group were injected with 0.9% NS 20ml thoracentesis each time. The other therapies in both groups were the same. Results The duration of pleural effusion absorption in the treatment groups was 18.3 （ ± 4. 2） days, whereas it was 22. 6 （ ± 5.6） days in the control group （P 〈 0. 05 ）. After two months treatment, the mean thickness of pleura in the treatment group was 1.00 （ ± 0.25 ） mm by B ultrasonic wave test, but it was 1.9（±0.46） mm in the control group（P 〈0.01 ）. The lung function （ FEV1% ） examined was 91.2% （ ±1.6% ） in the treatment group, while it was 86. 7% （± 4. 1% ） in the control（ P 〈 0. 01 ）. FVC% was 96. 7 % （ ± 1, 9% ） in the treatment group, while it was 86. 7 % （ ±4. 1% ） in the control group （P 〈 0. 01 ）. Conclusion Intmpleural urokinase through indwelling venous catheter not only reduces pleura/adlhesion, loculation and thickening of the pleura but also improves lung function.
出处
《临床肺科杂志》
2008年第10期1262-1263,共2页
Journal of Clinical Pulmonary Medicine
关键词
静脉导管
尿激酶
结核性胸膜炎
venous catheter
urokinase
tuberculosis pleurisy
